SE9901379D0 - Receptor structures - Google Patents

Receptor structures

Info

Publication number
SE9901379D0
SE9901379D0 SE9901379A SE9901379A SE9901379D0 SE 9901379 D0 SE9901379 D0 SE 9901379D0 SE 9901379 A SE9901379 A SE 9901379A SE 9901379 A SE9901379 A SE 9901379A SE 9901379 D0 SE9901379 D0 SE 9901379D0
Authority
SE
Sweden
Prior art keywords
domain
amino acid
acid residues
substitution
receptor structures
Prior art date
Application number
SE9901379A
Other languages
English (en)
Swedish (sv)
Inventor
Charlotta Ljungqvist
Karin Nord
Per-Aake Nygren
Mathias Uhlen
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9901379A priority Critical patent/SE9901379D0/xx
Publication of SE9901379D0 publication Critical patent/SE9901379D0/xx
Priority to US09/549,441 priority patent/US6602977B1/en
Priority to PCT/SE2000/000732 priority patent/WO2000063243A1/en
Priority to JP2000612330A priority patent/JP4578690B2/ja
Priority to DE60041052T priority patent/DE60041052D1/de
Priority to AU41624/00A priority patent/AU4162400A/en
Priority to EP00921293A priority patent/EP1179014B1/en
Priority to DK00921293T priority patent/DK1179014T3/da
Priority to AT00921293T priority patent/ATE417058T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SE9901379A 1999-04-19 1999-04-19 Receptor structures SE9901379D0 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9901379A SE9901379D0 (sv) 1999-04-19 1999-04-19 Receptor structures
US09/549,441 US6602977B1 (en) 1999-04-19 2000-04-14 Receptor structures
PCT/SE2000/000732 WO2000063243A1 (en) 1999-04-19 2000-04-17 Derivatives of the b or z domain from staphylococcal protein a (spa) interacting with at least one domain of human factor viii
JP2000612330A JP4578690B2 (ja) 1999-04-19 2000-04-17 ヒト第ｖｉｉｉ因子の少なくとも１ドメインと相互作用するスタフィロコッカスタンパク質ａ（ｓｐａ）由来のｂまたはｚドメインの誘導体
DE60041052T DE60041052D1 (de) 1999-04-19 2000-04-17 Derivate der z-domäne des proteins a von staphylococcus (spa), welche mit mindestens einer domäne des humanen faktors viii interagieren
AU41624/00A AU4162400A (en) 1999-04-19 2000-04-17 Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
EP00921293A EP1179014B1 (en) 1999-04-19 2000-04-17 Derivatives of the z domain from staphylococcal protein a (spa) interacting with at least one domain of human factor viii
DK00921293T DK1179014T3 (da) 1999-04-19 2000-04-17 Derivater af Z-domænet fra staphylococcalt protein A (SPA), som interagerer med mindst ét domæne fra human faktor VIII
AT00921293T ATE417058T1 (de) 1999-04-19 2000-04-17 Derivate der z-domäne des proteins a von staphylococcus (spa), welche mit mindestens einer domäne des humanen faktors viii interagieren

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901379A SE9901379D0 (sv) 1999-04-19 1999-04-19 Receptor structures

Publications (1)

Publication Number Publication Date
SE9901379D0 true SE9901379D0 (sv) 1999-04-19

Family

ID=20415254

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901379A SE9901379D0 (sv) 1999-04-19 1999-04-19 Receptor structures

Country Status (8)

Country Link
EP (1) EP1179014B1 (da)
JP (1) JP4578690B2 (da)
AT (1) ATE417058T1 (da)
AU (1) AU4162400A (da)
DE (1) DE60041052D1 (da)
DK (1) DK1179014T3 (da)
SE (1) SE9901379D0 (da)
WO (1) WO2000063243A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504261A (ja) * 2001-01-12 2005-02-10 アフィボディ・アーベー 検出方法
JP4554356B2 (ja) * 2002-04-29 2010-09-29 アフィボディ・アーベー サンドイッチアッセイおよびキット
ATE328906T1 (de) * 2002-06-28 2006-06-15 Domantis Ltd Dual-specifische liganden mit erhöhter halbwertszeit
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
SE0301936D0 (sv) * 2003-06-30 2003-06-30 Affibody Ab New polypeptide
JP4871126B2 (ja) * 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
SE0301987D0 (sv) * 2003-07-04 2003-07-04 Affibody Ab New polypeptide
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
WO2008127457A2 (en) 2006-12-06 2008-10-23 Repligen Corporation Nucleic acids encoding recombinant protein a
US7989216B2 (en) 2006-12-08 2011-08-02 General Electric Company Two helix binders
US7977118B2 (en) 2006-12-08 2011-07-12 General Electric Company Two helix binders
US7981691B2 (en) 2006-12-08 2011-07-19 General Electric Company Two helix binders
US8198043B2 (en) 2006-12-08 2012-06-12 General Electric Company Two helix binders
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
WO2009019117A1 (en) * 2007-08-03 2009-02-12 Affibody Ab Igf-1r binding polypeptides and their use
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
DK3241843T3 (da) 2008-06-25 2021-09-06 Novartis Ag Opløselighedsoptimering af immunbindere
US8592555B2 (en) 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
MX2011001583A (es) 2008-08-11 2011-04-04 Nektar Therapeutics Conjugados de alcanoato polimericos de multiples brazos.
EP2323695B1 (en) 2008-08-19 2018-12-05 Nektar Therapeutics Complexes of small-interfering nucleic acids
SG162687A1 (en) 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
JP5917417B2 (ja) 2010-03-05 2016-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体の選択的強化
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
SG10201604554WA (en) 2011-06-08 2016-07-28 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
EP3939613A1 (en) 2011-08-11 2022-01-19 ONO Pharmaceutical Co., Ltd. Therapeutic agent for autoimmune diseases comprising pd-1 agonist
NZ626620A (en) 2012-01-10 2016-07-29 Biogen Ma Inc Enhancement of transport of therapeutic molecules across the blood brain barrier
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
EP3489396B1 (en) 2012-12-27 2021-03-03 National Institute of Advanced Industrial Science and Technology Molecule library constructed on the basis of backbone structure of microprotein
EP3019520B1 (en) * 2013-07-10 2019-12-11 GE Healthcare BioProcess R&D AB Mutated immunoglobulin-binding polypeptides
JP7138411B2 (ja) * 2013-08-28 2022-09-16 アフィボディ・アーベー 変異した骨格を有する結合ポリペプチド
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
US20230399375A1 (en) 2022-04-15 2023-12-14 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
WO2023212704A2 (en) * 2022-04-29 2023-11-02 Tezcat Biosciences, Inc. Macropinocytosis selective non-binding protein-drug conjugates
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE468050C (sv) 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Rekombinant derivat av human faktor VIII
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures

Also Published As

Publication number Publication date
JP4578690B2 (ja) 2010-11-10
AU4162400A (en) 2000-11-02
WO2000063243A1 (en) 2000-10-26
EP1179014A1 (en) 2002-02-13
DK1179014T3 (da) 2009-04-06
ATE417058T1 (de) 2008-12-15
JP2002542259A (ja) 2002-12-10
EP1179014B1 (en) 2008-12-10
DE60041052D1 (de) 2009-01-22

Similar Documents

Publication Publication Date Title
SE9901379D0 (sv) Receptor structures
NO20063026L (no) Antistoffer
CY1116370T1 (el) ΔΙΑΛΥΤΗ ΓΛΥΚΟΠΡΩΤΕΪΝΗ ΥΑΛΟΥΡΟΝΙΔΑΣΗΣ (sHASEGP), ΔΙΑΔΙΚΑΣΙΑ ΓΙΑ ΤΗΝ ΠΑΡΑΣΚΕΥΗ ΤΗΣ, ΧΡΗΣΕΙΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΛΑΜΒΑΝΟΥΝ
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
NO964650L (no) LAG-3 proteinopploselige polypeptidfraksjoner, fremgangsmate for fremstilling, terapeutisk preparat og anti-idiotype antistoff
MA23856A1 (fr) Recombinant obese (ob) proteines
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69838143D1 (de) Antimikrobielle peptide
DE69820885D1 (de) Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde
NO20001600D0 (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
ATE229542T1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
SI1346034T1 (sl) POLIPEPTID PROTEAZE, KI CEPI VON WILLEBRANDOV FAKTOR (vWF), NUKLEINSKA KISLINA, KI KODIRA POLIPEPTID, IN UPORABA POLIPEPTIDA
ATE320488T1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
ATE193022T1 (de) Heparin-und sulfatid-bindende peptide vom typ 1 der wiederkehrenden sequenzen vom menschlichen thrombospondin
ATE322503T1 (de) Gefrierschutzprotein
RS49517B (sr) PEPTID p277-ANALOZI I FARMACEUTSKI PREPARATI KOJI GA SADRZE
FI970823A (fi) Uusia peptidijohdannaisia, joilla esiintyy delta-opioidireseptoreihin kohdistuvia antagonistisia vaikutuksia tai samanaikaisia my-agonistisia/delta-antagonistisia vaikutuksia
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
SE9003374D0 (sv) A collagen binding protein as well as its preparation
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
SE9602822D0 (sv) New receptor
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE294816T1 (de) Neue, physiologisch aktive peptide und ihre verwendung.
ES2094228T3 (es) Peptidos anticoagulantes.